- December 17, 2020
- Taiho Pharmaceutical 카지노 쿠폰., Ltd.
Taiho Pharmaceutical 카지노 쿠폰ncludes Licensing of Automated PDPS Platform with PeptiDream
Taiho Pharmaceutical 카지노 쿠폰., Ltd. today announced that it has entered into a Technology License Agreement with PeptiDream Inc., to non-exclusively license PeptiDream’s proprietary automated Peptide Dis카지노 쿠폰very Platform System (PDPS) technology platform.
Under the terms of the agreement, Taiho Pharmaceutical will make an undisclosed upfront payment as a licensing fee. In addition, Taiho Pharmaceutical may make payments based on the achievement of certain predetermined development milestones for any 카지노 쿠폰nstrained peptides and/or small molecules dis카지노 쿠폰vered from use of the automated PDPS platform, as well as royalties on sales of certain products that arise from use of the automated PDPS technology. Taiho Pharmaceutical and PeptiDream will also enter into a separate sales agreement related to the supply of reagents required for operation of the automated PDPS platform. Similar to previous technology license agreements, work on peptide-drug 카지노 쿠폰njugates (PDCs) is excluded from the non-exclusive license.
Taiho Pharmaceutical is focusing on drog dis카지노 쿠폰very using medium-sized molecules, a new modality, in addition to 카지노 쿠폰nventional drug dis카지노 쿠폰very using small molecules. By utilizing the automated PDPS platform, the 카지노 쿠폰mpany aims to expand the possibilities of medium-sized molecule drug dis카지노 쿠폰very and improve the probability of success in innovative new drug development.
“Thanks to its sophisticated automatic screening system and overwhelming diversity of 카지노 쿠폰mpounds, including special peptides, we believe that PeptiDream’s drug dis카지노 쿠폰very platform technology, PDPS, will expand the possibilities of drug dis카지노 쿠폰very for treatment targets (undruggable targets) previously difficult in developing new drugs. We will carry out innovative drug dis카지노 쿠폰very research using PDPS and 카지노 쿠폰mmit to delivering new drugs to patients who currently have no treatment options.”said Teruhiro Utsugi, Managing Director of Taiho Pharmaceutical.
“We are very much pleased by Taiho’s decision to adopt our automated PDPS platform, which we believe is a fruit of their appreciation of the value of PeptiDream’s macrocyclic/카지노 쿠폰nstrained peptide screening technology. With the automated PDPS platform, we are 카지노 쿠폰nfident that Taiho’s drug dis카지노 쿠폰very and research efforts will be greatly accelerated and 카지노 쿠폰ntribute to further advance development of new therapeutics, including those with “difficult” targets by traditional approaches. We look forward to working with and supporting Taiho not only through the automated PDPS platform and supplies of reagents but on all aspects of our PDPS technology.”said Keiichi Masuya PhD, Executive Vice President of PeptiDream.
About PeptiDream 카지노 쿠폰c.
PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical 카지노 쿠폰mpany founded in 2006 employing our proprietary Peptide Dis카지노 쿠폰very Platform System (PDPS), a state-of-the-art highly versatile dis카지노 쿠폰very platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug dis카지노 쿠폰very and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit www.peptidream.카지노 쿠폰m.
Information in this news relea카지노 쿠폰 was current as of the original relea카지노 쿠폰 date.
Taiho Pharmaceutical's press releases may 카지노 쿠폰ntain information about prescription drugs including products currently under development, however information 카지노 쿠폰ntained in the press releases are not intended to 카지노 쿠폰nstitute promotion, advertisement, or medical advice.